Company news
Laekna, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Voluntary announcement updates on the 24-week monotherapy study of LAE102 showed promising weight losses favorable changes in body composition and well tolerated safety profile
October 12, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
Interim Report 2026
September 18, 2026
New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
August 11, 2026
ADA 2025 | Laekna Presented Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123
June 23, 2025
Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA
March 3, 2025
Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024
December 11, 2024
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
November 20, 2024
Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer
May 23, 2024
Laekna Releases 2023 ESG Report
April 29, 2024
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024
January 3, 2024
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results
December 11, 2023
Laekna, Inc. (2105.HK) Announces Interim Results 2023
August 24, 2023